Caroline Seymour

Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.

Paul A. Bunn, Jr, MD, discusses how fam-trastuzumab deruxtecan-nxki could provide patients with metastatic non–small cell lung cancer who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy.

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.

Ghassan K. Abou-Alfa, MD, discusses the design and aim of the PROOF trial in advanced cholangiocarcinoma.

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.

The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

The downstream effects of the coronavirus disease 2019 on patients with cancer have become apparent over the past few months, and the onus is on the field to provide clinical guidance on best practices in the absence of definitive data.

There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.

KRAS mutations are found in approximately in 25% of all NSCLC, and it was not until recently that the previously coined “undruggable target” showed signals of actionability with KRAS mutation–specific therapy, tumor-suppressor–specific therapy, and anti-inflammatory therapy.

Patients 18 to 39 years of age with early-onset cancer had a significantly high risk of harboring germline mutations, suggesting that this population should undergo germline genetic testing, irrespective of tumor type.

A panel of hematologic experts came together for a live Q/A session to discuss promising research related to common clinical complications of hematopoietic stem cell transplantation.

CPX-351 continued to showcase an overall survival benefit versus conventional 7+3 chemotherapy in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.

Michael J. Morris, MD, discusses the results of the CONDOR trial and the utility of PSMA-targeted PET imaging in prostate cancer.

The combination of eprenetapopt and azacitidine led to high objective response rates and complete response rates in patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

The combination of venetoclax (Venclexta) and azacitidine led to a 34% reduction in the risk of death versus azacitidine alone in treatment-naïve patients with acute myeloid leukemia who are ineligible for intensive therapy.

The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma.

Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma.

Richard R. Furman, MD, discusses the findings from the analysis and highlights the differences between first- and second-generation BTK inhibitors in CLL.

Denise Yardley, MD, sheds light on individualized treatment approaches and other key developments in HER2-positive breast cancer.

Courtney DiNardo, MD, MSCE, discusses the results of the analysis evaluating the timing of response to venetoclax-based combinations, and related disease features, in older patients with AML.

The combination of pevonedistat and azacitidine led to a trend toward improved event-free survival and a numerical improvement in overall survival versus azacitidine alone in patients with higher-risk myelodysplastic syndrome/chronic myelomonocytic leukemia, and low-blast acute myelogenous leukemia.

The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.

Jia Ruan, MD, PhD, discusses the current risk-stratification parameters and the evolution of treatment from high-intensity chemoimmunotherapy to novel therapy in mantle cell lymphoma.

The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.